Figure 1.

Adherence levels at consecutive time points after starting tamoxifen therapy of 20 mg daily. (a) 3 months (n = 163); 6 months (n = 173); and 12 months (n = 170). (b) 12 months, stratified by the occurrence of self‐reported adverse events: presence of adverse events (Yes; N = 113); absence of adverse events (No; N = 57). Categories high (light grey), medium (dark grey), and low (black) are given as % for each group; P values refer to contingency Chi‐square tests of a difference between visit a or grouping by adverse events b.